FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4295117943> ?p ?o ?g. }

• W4295117943 abstract "Abstract Background Primary diffuse large B-cell lymphoma (DLBCL) of the central nervous system (PCNSL) is a rare disorder with an increasing incidence over the past decades. High-level evidence has been reported for the MATRix regimen (high-dose methotrexate (HD-MTX), high-dose AraC (HD-AraC), thiotepa and rituximab) followed by high-dose chemotherapy and autologous stem cell transplantation (HCT-ASCT) supporting this approach to be considered a standard therapy in newly diagnosed PCNSL patients ≤ 70 years. However, early treatment-related toxicities (predominantly infectious complications), occurring in up to 28% per MATRix cycle, diminish its therapeutic success. Furthermore, sensitivity to first-line treatment is an independent prognostic factor for improved overall survival (OS) in PCNSL. Thus, patients achieving early partial remission (PR) after 2 cycles of MATRix might be over-treated with 4 cycles, in the context of consolidation HCT-ASCT. Methods This is an open-label, multicentre, randomized phase III trial with two parallel arms. 326 immunocompetent patients with newly diagnosed PCNSL will be recruited from 37 German, 1 Austrian and 12 UK sites. Additional IELSG (International Extranodal Lymphoma Study Group) sites are planned. The objective is to demonstrate superiority of a de-escalated and optimised remission induction treatment strategy, followed by HCT-ASCT. Randomization (1:1) will be performed after completion of all screening procedures. Patients in Arm A (control treatment) will receive 4 cycles of MATRix. Patients in Arm B (experimental treatment) will receive a pre-phase (R/HD-MTX), followed by 2 cycles of MATRix. Patients in both arms achieving PR or better will proceed to HCT-ASCT (BCNU, thiotepa). The primary endpoint of the study is event-free-survival (EFS), defined as time from randomization to premature end of treatment due to any reason, lymphoma progression or death whichever occurs first. Secondary endpoints include OS, progression free survival (PFS), toxicity, neurocognitive impairment and quality of life. Minimal follow-up is 24 months. Discussion Current treatment options for PCNSL in patients ≤ 70 years have improved remarkably over recent years. However, the potential efficacy benefits are offset by an increased incidence of short-term toxicities which can impact on treatment delivery and hence on survival outcomes. In patients ≤ 70 years with newly diagnosed PCNSL addressing the need to reduce treatment-related toxicity by de-escalating and optimising the induction phase of treatment, is a potentially attractive treatment strategy. Trial registration German clinical trials registry DRKS00022768 registered June 10 th , 2021." @default.
• W4295117943 created "2022-09-10" @default.
• W4295117943 creator A5000276455 @default.
• W4295117943 creator A5010948621 @default.
• W4295117943 creator A5018113411 @default.
• W4295117943 creator A5020447255 @default.
• W4295117943 creator A5023417817 @default.
• W4295117943 creator A5045194637 @default.
• W4295117943 creator A5048078190 @default.
• W4295117943 creator A5049307026 @default.
• W4295117943 creator A5055238920 @default.
• W4295117943 creator A5056785499 @default.
• W4295117943 creator A5057483013 @default.
• W4295117943 creator A5073796875 @default.
• W4295117943 creator A5082526059 @default.
• W4295117943 date "2022-09-10" @default.
• W4295117943 modified "2023-10-01" @default.
• W4295117943 title "Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma" @default.
• W4295117943 cites W2070064504 @default.
• W4295117943 cites W2092261723 @default.
• W4295117943 cites W2108465006 @default.
• W4295117943 cites W2120766517 @default.
• W4295117943 cites W2135963804 @default.
• W4295117943 cites W2149603266 @default.
• W4295117943 cites W2164475514 @default.
• W4295117943 cites W2167352787 @default.
• W4295117943 cites W2294816409 @default.
• W4295117943 cites W2314481096 @default.
• W4295117943 cites W2338036651 @default.
• W4295117943 cites W2563063147 @default.
• W4295117943 cites W2766491362 @default.
• W4295117943 cites W3004116732 @default.
• W4295117943 cites W3046114750 @default.
• W4295117943 cites W3158097874 @default.
• W4295117943 cites W4244153997 @default.
• W4295117943 doi "https://doi.org/10.1186/s12885-022-09723-w" @default.
• W4295117943 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36088292" @default.
• W4295117943 hasPublicationYear "2022" @default.
• W4295117943 type Work @default.
• W4295117943 citedByCount "4" @default.
• W4295117943 countsByYear W42951179432023 @default.
• W4295117943 crossrefType "journal-article" @default.
• W4295117943 hasAuthorship W4295117943A5000276455 @default.
• W4295117943 hasAuthorship W4295117943A5010948621 @default.
• W4295117943 hasAuthorship W4295117943A5018113411 @default.
• W4295117943 hasAuthorship W4295117943A5020447255 @default.
• W4295117943 hasAuthorship W4295117943A5023417817 @default.
• W4295117943 hasAuthorship W4295117943A5045194637 @default.
• W4295117943 hasAuthorship W4295117943A5048078190 @default.
• W4295117943 hasAuthorship W4295117943A5049307026 @default.
• W4295117943 hasAuthorship W4295117943A5055238920 @default.
• W4295117943 hasAuthorship W4295117943A5056785499 @default.
• W4295117943 hasAuthorship W4295117943A5057483013 @default.
• W4295117943 hasAuthorship W4295117943A5073796875 @default.
• W4295117943 hasAuthorship W4295117943A5082526059 @default.
• W4295117943 hasBestOaLocation W42951179431 @default.
• W4295117943 hasConcept C126322002 @default.
• W4295117943 hasConcept C141071460 @default.
• W4295117943 hasConcept C143998085 @default.
• W4295117943 hasConcept C151730666 @default.
• W4295117943 hasConcept C2776611710 @default.
• W4295117943 hasConcept C2776694085 @default.
• W4295117943 hasConcept C2776755627 @default.
• W4295117943 hasConcept C2778559949 @default.
• W4295117943 hasConcept C2779050716 @default.
• W4295117943 hasConcept C2779338263 @default.
• W4295117943 hasConcept C2779343474 @default.
• W4295117943 hasConcept C2779968505 @default.
• W4295117943 hasConcept C2780140570 @default.
• W4295117943 hasConcept C2780653079 @default.
• W4295117943 hasConcept C2781173314 @default.
• W4295117943 hasConcept C2781413609 @default.
• W4295117943 hasConcept C2911091166 @default.
• W4295117943 hasConcept C71924100 @default.
• W4295117943 hasConcept C86803240 @default.
• W4295117943 hasConceptScore W4295117943C126322002 @default.
• W4295117943 hasConceptScore W4295117943C141071460 @default.
• W4295117943 hasConceptScore W4295117943C143998085 @default.
• W4295117943 hasConceptScore W4295117943C151730666 @default.
• W4295117943 hasConceptScore W4295117943C2776611710 @default.
• W4295117943 hasConceptScore W4295117943C2776694085 @default.
• W4295117943 hasConceptScore W4295117943C2776755627 @default.
• W4295117943 hasConceptScore W4295117943C2778559949 @default.
• W4295117943 hasConceptScore W4295117943C2779050716 @default.
• W4295117943 hasConceptScore W4295117943C2779338263 @default.
• W4295117943 hasConceptScore W4295117943C2779343474 @default.
• W4295117943 hasConceptScore W4295117943C2779968505 @default.
• W4295117943 hasConceptScore W4295117943C2780140570 @default.
• W4295117943 hasConceptScore W4295117943C2780653079 @default.
• W4295117943 hasConceptScore W4295117943C2781173314 @default.
• W4295117943 hasConceptScore W4295117943C2781413609 @default.
• W4295117943 hasConceptScore W4295117943C2911091166 @default.
• W4295117943 hasConceptScore W4295117943C71924100 @default.
• W4295117943 hasConceptScore W4295117943C86803240 @default.
• W4295117943 hasFunder F4320321114 @default.
• W4295117943 hasIssue "1" @default.
• W4295117943 hasLocation W42951179431 @default.
• W4295117943 hasLocation W42951179432 @default.
• W4295117943 hasLocation W42951179433 @default.
• W4295117943 hasLocation W42951179434 @default.

• next